Summit Trail Advisors LLC Buys 322 Shares of Danaher Co. (NYSE:DHR)

Summit Trail Advisors LLC raised its stake in Danaher Co. (NYSE:DHR) by 3.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 10,871 shares of the conglomerate’s stock after buying an additional 322 shares during the quarter. Summit Trail Advisors LLC’s holdings in Danaher were worth $2,719,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after buying an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares during the last quarter. Swedbank AB acquired a new position in shares of Danaher during the first quarter valued at about $676,545,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after buying an additional 1,619,586 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Down 1.4 %

Shares of Danaher stock opened at $272.63 on Friday. The stock has a 50 day moving average of $267.62 and a 200 day moving average of $257.14. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The firm has a market capitalization of $201.93 billion, a price-to-earnings ratio of 46.21, a PEG ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.05 EPS. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. As a group, research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 in the last ninety days. 11.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. The Goldman Sachs Group lifted their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Bank of America raised their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Barclays upped their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.